Frontiers in Pharmacology | Drugs Outcomes Research and Policies

Original Research

Published on 24 Dec 2021

Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB–IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care System in China

in Drugs Outcomes Research and Policies

Chen Zhu
Xiao-xuan Xing
Bin Wu
Gang Liang
Gang Han
Cai-xia Lin
Hong-mei Fang

Frontiers in Pharmacology

doi 10.3389/fphar.2021.735536

5,172 views
22 citations

Original Research

Published on 23 Dec 2021

What Is Valued Most by Patients With Type 2 Diabetes Mellitus When Selecting Second-Line Antihyperglycemic Medications in China

in Drugs Outcomes Research and Policies

Shimeng Liu
Jing Liu
Yijiang Yu
Lei Si
Chengxiang Tang
Zhigang Liu
Yingyao Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2021.802897

2,632 views
3 citations

Original Research

Published on 22 Dec 2021

Household Drug Stockpiling and Panic Buying of Drugs During the COVID-19 Pandemic: A Study From Jordan

in Drugs Outcomes Research and Policies

Sura Al Zoubi
Lobna Gharaibeh
Hatim M. Jaber
Zaha Al-Zoubi

Frontiers in Pharmacology

doi 10.3389/fphar.2021.813405

6,724 views
24 citations

General Commentary

Published on 22 Dec 2021

Commentary: New Viscoelastic Hydrogel Hymovis MORE Single Intra-Articular Injection for the Treatment of Knee Osteoarthritis in Sportsmen: Safety and Efficacy Study Results

in Drugs Outcomes Research and Policies

Thierry Conrozier
Thomas Lohse

Frontiers in Pharmacology

doi 10.3389/fphar.2021.785074

2,417 views

Review

Published on 21 Dec 2021

Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders

in Drugs Outcomes Research and Policies

Sweta Shah
Marc Marie Dooms
Sofia Amaral-Garcia
Mariana Igoillo-Esteve

Frontiers in Pharmacology

doi 10.3389/fphar.2021.768023

19,922 views
36 citations

Original Research

Published on 21 Dec 2021

First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis

in Drugs Outcomes Research and Policies

Qiao Liu
Zhen Zhou
Xia Luo
Lidan Yi
Liubao Peng
Xiaomin Wan
Chongqing Tan
Xiaohui Zeng

Frontiers in Pharmacology

doi 10.3389/fphar.2021.788569

4,737 views
19 citations

Original Research

Published on 21 Dec 2021

The Public Health Insurance Coverage of Novel Targeted Anticancer Medicines in China—In Favor of Whom? A Retrospective Analysis of the Insurance Claim Data

in Drugs Outcomes Research and Policies

Mingshuang Li
Yifan Diao
Jianchun Ye
Jing Sun
Yu Jiang

Frontiers in Pharmacology

doi 10.3389/fphar.2021.778940

2,353 views
9 citations

Original Research

Published on 21 Dec 2021

Efficacy and Safety of Anti–Vascular Endothelial Growth Factor Monotherapies for Neovascular Age-Related Macular Degeneration: A Mixed Treatment Comparison

in Drugs Outcomes Research and Policies

Yun Zhang
Sheng Gao
Xun Li
Xi Huang
Yi Zhang
Tiancong Chang
Zhaolun Cai
Meixia Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2021.797108

4,720 views
11 citations

Policy and Practice Reviews

Published on 16 Dec 2021

Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)

in Drugs Outcomes Research and Policies

Annemieke Aartsma-Rus
Marc Dooms
Yann Le Cam

Frontiers in Pharmacology

doi 10.3389/fphar.2021.744532

13,001 views
30 citations

Editorial

Published on 15 Dec 2021

Editorial: Deprescribing and Minimizing Use of Anticholinergic Medications

in Drugs Outcomes Research and Policies

Roy L. Soiza
Malaz A. Boustani
Noll L. Campbell
Arduino A. Mangoni

Frontiers in Pharmacology

doi 10.3389/fphar.2021.820051

2,242 views
4 citations

Original Research

Published on 14 Dec 2021

Treatment Dynamics in People Who Initiate Metformin or Sulfonylureas for Type 2 Diabetes: A National Cohort Study

in Drugs Outcomes Research and Policies

Stephen Wood
Dianna J. Magliano
J Simon Bell
Jonathan E. Shaw
Jenni Ilomäki

Frontiers in Pharmacology

doi 10.3389/fphar.2021.794273

2,642 views
3 citations

Original Research

Published on 14 Dec 2021

Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer

in Drugs Outcomes Research and Policies

Tan Chongqing
Li Sini
Zeng Xiaohui
Peng Liubao
Peng Ye
Qin Shuxia
Wang Liting
Wu Meiyu
Wan Xiaomin

Frontiers in Pharmacology

doi 10.3389/fphar.2021.802942

4,446 views
9 citations

Correction

Published on 14 Dec 2021

Corrigendum: Evaluation of Adverse Drug Reactions in Paediatric Patients: A Retrospective Study in Turkish Hospital

in Drugs Outcomes Research and Policies

Zakir Khan
Yusuf Karataş
Olcay Kıroğlu

Frontiers in Pharmacology

doi 10.3389/fphar.2021.813892

935 views

Perspective

Published on 14 Dec 2021

Crowd Funding for Orphan Drugs: The Case of Baby Pia

in Drugs Outcomes Research and Policies

Wim Pinxten

Frontiers in Pharmacology

doi 10.3389/fphar.2021.787342

4,646 views
3 citations

Systematic Review

Published on 13 Dec 2021

A Systematic Review of Economic Evaluations of Active Tuberculosis Treatments

in Drugs Outcomes Research and Policies

Joo-Young Byun
Hye-Lin Kim
Eui-Kyung Lee
Sun-Hong Kwon

Frontiers in Pharmacology

doi 10.3389/fphar.2021.736986

5,726 views
7 citations

Original Research

Published on 13 Dec 2021

The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia

in Drugs Outcomes Research and Policies

Tomas Tesar
Peter Golias
Lucia Masarykova
Paweł Kawalec
András Inotai

Frontiers in Pharmacology

doi 10.3389/fphar.2021.795002

5,823 views
5 citations

Navigation group

Articles

Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB–IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care System in China

What Is Valued Most by Patients With Type 2 Diabetes Mellitus When Selecting Second-Line Antihyperglycemic Medications in China

Household Drug Stockpiling and Panic Buying of Drugs During the COVID-19 Pandemic: A Study From Jordan

Commentary: New Viscoelastic Hydrogel Hymovis MORE Single Intra-Articular Injection for the Treatment of Knee Osteoarthritis in Sportsmen: Safety and Efficacy Study Results

Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders

First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis

The Public Health Insurance Coverage of Novel Targeted Anticancer Medicines in China—In Favor of Whom? A Retrospective Analysis of the Insurance Claim Data

Efficacy and Safety of Anti–Vascular Endothelial Growth Factor Monotherapies for Neovascular Age-Related Macular Degeneration: A Mixed Treatment Comparison

Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)

Editorial: Deprescribing and Minimizing Use of Anticholinergic Medications

Treatment Dynamics in People Who Initiate Metformin or Sulfonylureas for Type 2 Diabetes: A National Cohort Study

Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer

Corrigendum: Evaluation of Adverse Drug Reactions in Paediatric Patients: A Retrospective Study in Turkish Hospital

Crowd Funding for Orphan Drugs: The Case of Baby Pia

A Systematic Review of Economic Evaluations of Active Tuberculosis Treatments

The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia